United States securities and exchange commission logo

                          July 14, 2022

       Joern Aldag
       Chief Executive Officer
       HOOKIPA Pharma Inc.
       350 Fifth Avenue, 72nd Floor, Suite 7240
       New York, NY 10118

                                                        Re: HOOKIPA Pharma Inc.
Statement on Form S-3
                                                            Filed July 12, 2022
                                                            File No. 333-266104

       Dear Mr. Aldag:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jason
Drory at 202-551-8342 with any questions.


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Seo Salimi, Esq.